Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease

Journal of Neuroimmunology

Volumn 244, Issue 1-2, 2012, Pages 70-83

  Kou, Jinghong ^a   Song, Min ^a,b   Pattanayak, Abhinandan ^a   Lim, Jeong Eun ^a   Yang, Junling ^a   Cao, Dongfeng ^c   Li, Ling ^c   Fukuchi, Ken ichiro ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Adenovirus; Alzheimer's disease; Amyloid; Inflammation; Statin; Vaccine

Indexed keywords

AMYLOID BETA PROTEIN; DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRIMER DNA; SIMVASTATIN;

ADENOVIRUS; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIPPOCAMPUS; IMMUNIZATION; IMMUNOREACTIVITY; LEUKOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; CEREBRAL AMYLOID ANGIOPATHY; DISEASE MODELS, ANIMAL; FEMALE; HIPPOCAMPUS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SIMVASTATIN;

EID: 84862813698     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.01.008     Document Type: Article

References (82)

1. Agadjanyan M.G., Ghochikyan A., Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., Saing T., Cribbs D.H. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 2005, 174:1580-1586.
2. Altman R., Rutledge J.C. The vascular contribution to Alzheimer's disease. Clin. Sci. (Lond) 2010, 119:407-421.
3. Arora M., Chen L., Paglia M., Gallagher I., Allen J.E., Vyas Y.M., Ray A., Ray P. Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7777-7782.
4. Bacskai B.J., Kajdasz S.T., McLellan M.E., Games D., Seubert P., Schenk D., Hyman B.T. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 2002, 22:7873-7878.
5. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
6. Bhat N.R. Linking cardiometabolic disorders to sporadic Alzheimer's disease: a perspective on potential mechanisms and mediators. J. Neurochem. 2010, 115:551-562.
7. Boche D., Zotova E., Weller R.O., Love S., Neal J.W., Pickering R.M., Wilkinson D., Holmes C., Nicoll J.A. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008, 131:3299-3310.
8. Boche D., Denham N., Holmes C., Nicoll J.A. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol. 2010, 120:369-384.
9. Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature 2002, 415:462.
10. Citron M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 2010, 9:387-398.
11. Cribbs D.H., Ghochikyan A., Vasilevko V., Tran M., Petrushina I., Sadzikava N., Babikyan D., Kesslak P., Kieber-Emmons T., Cotman C.W., Agadjanyan M.G. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 2003, 15:505-514.
12. Damas J.K., Boullier A., Waehre T., Smith C., Sandberg W.J., Green S., Aukrust P., Quehenberger O. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2567-2572.
13. Das K.P., Chao S.L., White L.D., Haines W.T., Harry G.J., Tilson H.A., Barone S. Differential patterns of nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3 mRNA and protein levels in developing regions of rat brain. Neuroscience 2001, 103:739-761.
14. Das P., Murphy M.P., Younkin L.H., Younkin S.G., Golde T.E. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging 2001, 22:721-727.
15. Ferrer I., Boada R.M., Sanchez Guerra M.L., Rey M.J., Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004, 14:11-20.
16. Fonseca A.C., Proenca T., Resende R., Oliveira C.R., Pereira C.M. Neuroprotective effects of statins in an in vitro model of Alzheimer's disease. J. Alzheimers Dis. 2009, 17:503-517.
17. Garcia-Alloza M., Ferrara B.J., Dodwell S.A., Hickey G.A., Hyman B.T., Bacskai B.J. A limited role for microglia in antibody mediated plaque clearance in APP mice. Neurobiol. Dis. 2007, 28:286-292.
18. Gelinas D.S., DaSilva K., Fenili D., George-Hyslop P., McLaurin J. Immunotherapy for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14657-14662.
19. Ghittoni R., Lazzerini P.E., Pasini F.L., Baldari C.T. T lymphocytes as targets of statins: molecular mechanisms and therapeutic perspectives. Inflamm. Allergy Drug Targets 2007, 6:3-16.
20. Ghochikyan A., Petrushina I., Lees A., Vasilevko V., Movsesyan N., Karapetyan A., Agadjanyan M.G., Cribbs D.H. Abeta-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugates. DNA Cell Biol. 2006, 25:571-580.
21. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
22. Goni F., Sigurdsson E.M. New directions towards safer and effective vaccines for Alzheimer's disease. Curr. Opin. Mol. Ther. 2005, 7:17-23.
23. Hakamada-Taguchi R., Uehara Y., Kuribayashi K., Numabe A., Saito K., Negoro H., Fujita T., Toyo-oka T., Kato T. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ. Res. 2003, 93:948-956.
24. Han K.H., Ryu J., Hong K.H., Ko J., Pak Y.K., Kim J.B., Park S.W., Kim J.J. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 2005, 111:1439-1447.
25. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
26. Ifergan I., Wosik K., Cayrol R., Kebir H., Auger C., Bernard M., Bouthillier A., Moumdjian R., Duquette P., Prat A. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann. Neurol. 2006, 60:45-55.
27. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13:45-53.
28. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., Borchelt D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004, 13:159-170.
29. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
30. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
31. Kim H.D., Maxwell J.A., Kong F.K., Tang D.C., Fukuchi K. Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease. Biochem. Biophys. Res. Commun. 2005, 336:84-92.
32. Kim H.D., Jin J.J., Maxwell J.A., Fukuchi K. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol. Lett. 2007, 112:30-38.
33. Kim H.D., Tahara K., Maxwell J.A., Lalonde R., Fukuiwa T., Fujihashi K., Van Kampen K.R., Kong F.K., Tang D.C., Fukuchi K.I. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J. Gene Med. 2007, 9:88-98.
34. Kou J., Kim H.D., Jin J., Cao D., Li L., Lalonde R., Fukuchi K. Simvastatin enhances immune responses to Abeta vaccination and attenuates vaccination-induced behavioral alterations. Brain Res. 2010, 1356:102-111.
35. Lambert M.P., Viola K.L., Chromy B.A., Chang L., Morgan T.E., Yu J., Venton D.L., Krafft G.A., Finch C.E., Klein W.L. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 2001, 79:595-605.
36. Lee E.B., Leng L.Z., Lee V.M., Trojanowski J.Q. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett. 2005, 579:2564-2568.
37. Lee P.Y., Scumpia P.O., Byars J.A., Kelly K.M., Zhuang H., Shuster J.S., Theriaque D.W., Segal M.S., Reeves W.H., Brantly M.L. Short-term atorvastatin treatment enhances specific antibody production following tetanus toxoid vaccination in healthy volunteers. Vaccine 2006, 24:4035-4040.
38. Li L., Cao D., Kim H., Lester R., Fukuchi K. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann. Neurol. 2006, 60:729-739.
39. Luzzi S., Vella L., Bartolini M., Provinciali L., Silvestrini M. Atherosclerosis in the evolution of Alzheimer's disease: can treatment reduce cognitive decline?. J. Alzheimers Dis. 2010, 20:893-901.
40. Menge T., Hartung H.P., Stuve O. Statins-a cure-all for the brain?. Nat. Rev. Neurosci. 2005, 6:325-331.
41. Miida T., Takahashi A., Ikeuchi T. Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects. Pharmacol. Ther. 2007, 113:378-393.
42. Minami S.S., Sidahmed E., Aid S., Shimoji M., Niikura T., Mocchetti I., Rebeck G.W., Prendergast J.S., Dealwis C., Wetzel R., Bosetti F., Matsuoka Y., Hoe H.S., Turner R.S. Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Abeta/amyloid burden in a transgenic mouse model of Alzheimer's disease. J. Neuroinflammation 2010, 7:57.
43. Monsonego A. Immunogenic aspects of amyloid B-peptide: implications for pathogenesis and treatment of Alzheimer's disease. Proceedings VIII Conference on Alzheimer's Disease and Related Disorders 2005, 423.
44. Monsonego A., Weiner H.L. Immunotherapeutic approaches to Alzheimer's disease. Science 2003, 302:834-838.
45. Monsonego A., Maron R., Zota V., Selkoe D.J., Weiner H.L. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10273-10278.
46. Monsonego A., Imitola J., Petrovic S., Zota V., Nemirovsky A., Baron R., Fisher Y., Owens T., Weiner H.L. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5048-5053.
47. Morgan D. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. Neurochem. Int. 2006, 49:190-194.
48. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
49. Movsesyan N., Davtyan H., Mkrtichyan M., Petrushina I., Tiraturyan T., Ross T., Agadjanyan M.G., Ghochikyan A., Cribbs D.H. Low concentrations of anti-Abeta antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology. Hum. Gene Ther. 2010, 21:1569-1576.
50. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448-452.
51. Nicoll J.A., Barton E., Boche D., Neal J.W., Ferrer I., Thompson P., Vlachouli C., Wilkinson D., Bayer A., Games D., Seubert P., Schenk D., Holmes C. Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol. 2006, 65:1040-1048.
52. Okura Y., Miyakoshi A., Kohyama K., Park I.K., Staufenbiel M., Matsumoto Y. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:9619-9624.
53. Opalka D., Lachman C.E., MacMullen S.A., Jansen K.U., Smith J.F., Chirmule N., Esser M.T. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin. Diagn. Lab. Immunol. 2003, 10:108-115.
54. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
55. Pahan K., Sheikh F.G., Namboodiri A.M., Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 1997, 100:2671-2679.
56. Patton R.L., Kalback W.M., Esh C.L., Kokjohn T.A., Van Vickle G.D., Luehrs D.C., Kuo Y.M., Lopez J., Brune D., Ferrer I., Masliah E., Newel A.J., Beach T.G., Castano E.M., Roher A.E. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am. J. Pathol. 2006, 169:1048-1063.
57. Petrushina I., Ghochikyan A., Mktrichyan M., Mamikonyan G., Movsesyan N., Davtyan H., Patel A., Head E., Cribbs D.H., Agadjanyan M.G. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J. Neurosci. 2007, 27:12721-12731.
58. Petrushina I., Ghochikyan A., Mkrtichyan M., Mamikonyan G., Movsesyan N., Ajdari R., Vasilevko V., Karapetyan A., Lees A., Agadjanyan M.G., Cribbs D.H. Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J. Neuroinflammation 2008, 5:42.
59. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M., Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002, 298:1379.
60. Pifer J., Hennes J.L., Lee J.M., Witte P.L. Age-related differences in the immune response to immunization with human Abeta42 peptide. J. Gerontol. A Biol. Sci. Med. Sci. 2002, 57:B355-B358.
61. Racke M.M., Boone L.I., Hepburn D.L., Parsadainian M., Bryan M.T., Ness D.K., Piroozi K.S., Jordan W.H., Brown D.D., Hoffman W.P., Holtzman D.M., Bales K.R., Gitter B.D., May P.C., Paul S.M., DeMattos R.B. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 2005, 25:629-636.
62. Rezai-Zadeh K., Gate D., Gowing G., Town T. How to get from here to there: macrophage recruitment in Alzheimer's disease. Curr. Alzheimer Res. 2011, 8:156-163.
63. Rockwood K., Kirkland S., Hogan D.B., MacKnight C., Merry H., Verreault R., Wolfson C., McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 2002, 59:223-227.
64. Savage M.J., Kawooya J.K., Pinsker L.R., Emmons T.L., Mistretta S.S.R., Greenberg B.D. Elevated A-beta levels in Alzheimer's disease brain are associated with selective accumulation of A-beta 42 in parenchymal amyloid plaques and both A-beta40 and A-beta42 in cerebrovascular deposits. Int. J. Exp. Clin. Invest. 1995, 2:234-240.
65. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
66. Schenk D., Hagen M., Seubert P. Current progress in beta-amyloid immunotherapy. Curr. Opin. Immunol. 2004, 16:599-606.
67. Seabrook T.J., Thomas K., Jiang L., Bloom J., Spooner E., Maier M., Bitan G., Lemere C.A. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol. Aging 2007, 28:813-823.
68. Shimada K., Park J.K., Daida H. T helper 1/T helper 2 balance and HMG-CoA reductase inhibitors in acute coronary syndrome: statins as immunomodulatory agents?. Eur. Heart J. 2006, 27:2916-2918.
69. Shinohara M., Sato N., Kurinami H., Takeuchi D., Takeda S., Shimamura M., Yamashita T., Uchiyama Y., Rakugi H., Morishita R. Reduction of brain A{beta} by fluvastatin, an HMG-CoA reductase inhibitor, through increase in degradation of APP-CTFs and A{beta} clearance. J. Biol. Chem. 2010, 285:22091-22102.
70. Uro-Coste E., Russano de Paiva G., Guilbeau-Frugier C., Sastre N., Ousset P.J., da Silva N.A., Lavialle-Guillotreau V., Vellas B., Delisle M.B. Cerebral amyloid angiopathy and microhemorrhages after amyloid beta vaccination: case report and brief review. Clin. Neuropathol. 2010, 29:209-216.
71. Van Dorpe J., Smeijers L., Dewachter I., Nuyens D., Spittaels K., Van Den Haute C., Mercken M., Moechars D., Laenen I., Kuiperi C., Bruynseels K., Tesseur I., Loos R., Vanderstichele H., Checler F., Sciot R., Van L.F. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am. J. Pathol. 2000, 157:1283-1298.
72. Veillard N.R., Braunersreuther V., Arnaud C., Burger F., Pelli G., Steffens S., Mach F. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006, 188:51-58.
73. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
74. Wiessner C., Wiederhold K.H., Tissot A.C., Frey P., Danner S., Jacobson L.H., Jennings G.T., Luond R., Ortmann R., Reichwald J., Zurini M., Mir A., Bachmann M.F., Staufenbiel M. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J. Neurosci. 2011, 31:9323-9331.
75. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 2004, 1:24.
76. Willey J.Z., Elkind M.S. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch. Neurol. 2010, 67:1062-1067.
77. Wisniewski T., Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol. 2005, 15:72-77.
78. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000, 57:1439-1443.
79. Wolozin B., Manger J., Bryant R., Cordy J., Green R.C., McKee A. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol. Scand. Suppl. 2006, 185:63-70.
80. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84.
81. Zeng L., Xu H., Chew T.L., Eng E., Sadeghi M.M., Adler S., Kanwar Y.S., Danesh F.R. HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation. FASEB J. 2005, 19:1845-1847.
82. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.